Diamind Solutions

AcT QuICR Trial

One of the first projects on our DCTMS platform, the AcT trial is a Pragmatic Phase III randomized open-label registry-based trial with blinded end-point assessment. The trial seeks to test whether intravenous tenecteplase (an intravenous thrombolytic drug tested and found safe in multiple phase 2 and one phase 3 trial is patients with acute ischemic stroke) can replace intravenous alteplase (the current standard care) in patients who are otherwise eligible to receive the latter in routine care.

ACT-QUICR is a custom designed Electronic Data Capture (EDC) and Randomization Solution with the purpose of facilitating the data collection for the ACT-QUICR trial, while providing the following functions:

  • Provides participating trial physicians with the physician script
  • Provides patients with relevant patient information
  • Allow randomization of subjects based on the presented protocol
  • Provide functionality for validating the randomization of subjects
  • Enable paper and electronic subject consent acquisition
  • Sends out periodic notifications to enrolled sites
  • Dashboards, charts and reports
  • Secure & Scalable

Want to know more about DCTMS? Please visit our DCTMS Product page or contact us for a free demo!

Other Links:

Ready to enroll?Get started today!

Our main areas of expertise are in the Healthcare, Academic, Education as well as the Energy Sector, where we provide solutions for a number of needs:

  • - Clinical Trial Management Solutions (CTMS)
  • - Interactive Response Technologies (IRT)
  • - Randomization & Drug Management
  • - Document Management & eTMF
  • - eConsent
  • - EHR Integrations
  • - Custom Application Development
  • - Business Intelligence & Data Integration

Contact Us
App screenshot